Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alprostadil - PowderJect

Next Previous
X
Search
Drug Profile

Alprostadil - PowderJect

Alternative Names: Prostaglandin E1 - PowderJect

Latest Information Update: 23 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PowderJect Pharmaceuticals; PowderJect Therapeutics
  • Developer Evotec AG; PowderJect Pharmaceuticals; PowderJect Therapeutics
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 13 Dec 2000 Discontinued-II for Erectile dysfunction in United Kingdom (Injection)
  • 10 Feb 2000 PowderJect has completed a phase II trial of alprostadil in patients with erectile dysfunction
  • 20 Jul 1999 Two clinical studies have been added to the adverse events and pharmacodynamics sections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top